When comparing Ozempic vs Wegovy vs Mounjaro for weight loss, Mounjaro (tirzepatide) produces the greatest average weight loss — approximately 20.9% of body weight over 72 weeks in the SURMOUNT-1 trial — compared to Wegovy’s (semaglutide 2.4 mg) 14.9% over 68 weeks in STEP 1. However, only Wegovy and Mounjaro are FDA-approved specifically for weight management; Ozempic is licensed for type 2 diabetes and is frequently prescribed off-label for weight loss. The best drug for you depends on your individual health profile, insurance coverage, and tolerance for side effects.

I prescribe all three of these medications in my endocrinology practice, and I’m often asked which one I’d recommend. My honest answer: Mounjaro (or its weight-management formulation, Zepbound) tends to produce more weight loss on average, but individual responses vary enormously. I’ve had patients lose 25% of their body weight on Wegovy and patients who barely lost 8% on Mounjaro. The right medication is the one that works for your physiology and that you can take consistently and safely.

Understanding GLP-1 Medications: The Key Differences

Ozempic, Wegovy, and Mounjaro are all injectable medications that target the GLP-1 (glucagon-like peptide-1) receptor system to suppress appetite and improve metabolic health — but they work in subtly different ways.

• Ozempic (semaglutide): A GLP-1 receptor agonist approved for type 2 diabetes. Available at doses of 0.5 mg, 1.0 mg, and 2.0 mg weekly.
• Wegovy (semaglutide): The same active ingredient as Ozempic at a higher dose (up to 2.4 mg weekly), specifically approved for weight management in adults with obesity or overweight with at least one weight-related condition.
• Mounjaro/Zepbound (tirzepatide): A dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management. Available at doses up to 15 mg weekly.

The key distinction for Mounjaro is its dual mechanism. By targeting both GLP-1 and GIP receptors simultaneously, tirzepatide achieves stronger appetite suppression and greater metabolic effects than semaglutide alone. This dual action is the likely explanation for its superior weight loss outcomes in clinical trials.

Ozempic vs Wegovy: Are They Really Different?

Same Drug, Different Doses

Ozempic and Wegovy contain the exact same active ingredient — semaglutide — manufactured by Novo Nordisk. The primary difference is the approved maximum dose: 2.0 mg for Ozempic versus 2.4 mg for Wegovy. Because weight loss is dose-dependent with semaglutide, Wegovy is generally more effective for weight management than Ozempic at its maximum approved diabetes dose.

Weight Loss Comparison

Wegovy at 2.4 mg produced a mean weight loss of 14.9% of body weight over 68 weeks in the STEP 1 trial. Ozempic at 1.0 mg — the typical dose used for type 2 diabetes — produced around 8–10 lbs of weight loss in initial clinical trials at 30 weeks. When Ozempic is used at its maximum dose of 2.0 mg, weight loss approaches but doesn’t quite reach Wegovy’s outcomes.

Approved Indications

This matters practically for insurance coverage. Ozempic is covered by most insurance plans for type 2 diabetes. Wegovy is approved for obesity treatment (BMI ≥30, or ≥27 with a weight-related condition) and is covered by an increasing number of insurance plans, though coverage remains patchy in many markets. If you have type 2 diabetes, Ozempic may be the more accessible option. If your primary goal is weight management, Wegovy is the on-label choice.

Wegovy vs Mounjaro: Which Produces More Weight Loss?

The Head-to-Head Evidence

Direct head-to-head randomised trial data comparing semaglutide and tirzepatide is now available. A 2024 study published in JAMA Internal Medicine, analysing real-world data from nearly 19,000 patients, found that tirzepatide produced significantly greater weight loss than semaglutide at all time points. At 12 months, the difference in on-treatment weight loss was −6.9 percentage points in favour of tirzepatide (95% CI: −7.9% to −5.8%). Patients on tirzepatide were 1.76 times more likely to achieve ≥5% weight loss, 2.54 times more likely to achieve ≥10%, and 3.24 times more likely to achieve ≥15%.

The SURMOUNT-1 trial data for tirzepatide is compelling: at 72 weeks, the 15 mg dose produced a mean weight loss of 20.9%, with approximately 91% of patients achieving at least 5% weight loss and around 57% achieving at least 20% weight loss. This compares to 50.5% of participants achieving ≥15% weight loss on Wegovy in STEP 1.

A Zepbound vs Wegovy Note

A recent direct head-to-head trial (SURMOUNT-5) confirmed greater weight loss with tirzepatide (Zepbound) compared to semaglutide (Wegovy). Participants on the higher doses of tirzepatide consistently outperformed semaglutide. For patients whose primary goal is maximum weight loss and who do not have significant contraindications, tirzepatide currently represents the more potent option.

Side Effects Comparison

What They Have in Common

All three medications share the same core side effect profile: nausea, vomiting, diarrhoea, constipation, and abdominal pain. These are gastrointestinal effects linked to their shared mechanism of slowing gastric emptying. Side effects are most prominent during dose escalation and typically improve significantly once the maintenance dose is reached and the body adapts.

In clinical trials, the most common adverse events with both semaglutide and tirzepatide were gastrointestinal, classified as mild to moderate in the vast majority of cases. Discontinuation rates due to GI side effects were around 4–7% in the major trials.

Differences in Side Effect Profile

Mounjaro tends to cause slightly higher rates of nausea during the escalation period compared to Wegovy, likely due to its dual GIP/GLP-1 mechanism. However, real-world comparative data from the 2024 JAMA Internal Medicine study found that rates of gastrointestinal adverse events were broadly similar between tirzepatide and semaglutide-treated patients.

Dosing Schedules Compared

Cost and Availability

Without insurance, all three medications are expensive — typically $900–$1,400 per month in the United States without manufacturer coupons or insurance coverage. Novo Nordisk’s savings card can reduce Wegovy costs significantly for eligible patients. Eli Lilly offers similar savings programmes for Mounjaro and Zepbound.

Compounded semaglutide and tirzepatide became widely available in the US during the shortage periods of 2022–2024 but the FDA has taken steps to restrict compound pharmacy production as supplies normalise. Always ensure any compounded GLP-1 medication comes from a licensed 503B outsourcing facility and is prescribed by a licensed physician.

Which GLP-1 Should You Choose?

Here’s how I guide patients in my practice:

• You have type 2 diabetes and need weight loss: Ozempic or Mounjaro. Both are approved for T2D and both produce clinically meaningful weight loss. Mounjaro produces greater HbA1c reductions and more weight loss.
• Your primary goal is maximum weight loss and you don’t have T2D: Wegovy or Zepbound. If tolerance and cost allow, tirzepatide (Zepbound) produces greater weight loss on average.
• You’re concerned about side effects: Start with semaglutide. The escalation schedule is well-established and most patients tolerate it well.
• Insurance will only cover one option: Take what you can get consistently. Adherence over time matters more than which drug you’re on.

Frequently Asked Questions

Q: Is Mounjaro stronger than Ozempic for weight loss?

Yes. Clinical trial data consistently shows tirzepatide (Mounjaro/Zepbound) produces greater average weight loss than semaglutide (Ozempic/Wegovy). A 2024 real-world study in JAMA Internal Medicine found tirzepatide users lost an average of 6.9 percentage points more body weight than semaglutide users over 12 months. However, both medications produce clinically meaningful weight loss, and individual responses vary considerably.

Q: Can you switch from Ozempic to Wegovy?

Yes, and this is often done when the goal shifts from blood sugar management to dedicated weight management. Since both contain semaglutide, the transition is relatively straightforward — your prescriber will determine the appropriate starting dose for Wegovy based on your current Ozempic dose. Never switch medications without medical supervision.

Q: Is Wegovy the same as Ozempic?

They contain the same active ingredient (semaglutide) and are made by the same manufacturer (Novo Nordisk). The key differences are the approved indications — Ozempic for type 2 diabetes, Wegovy for weight management — and the maximum dose: 2.0 mg for Ozempic versus 2.4 mg for Wegovy. The higher dose in Wegovy contributes to its greater weight loss efficacy.

Q: What are the long-term risks of GLP-1 medications?

GLP-1 medications carry a small risk of pancreatitis, and there is a class-wide boxed warning regarding a potential risk of thyroid C-cell tumours (observed in rodent studies at high doses; not confirmed in humans at clinical doses). They should not be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Long-term cardiovascular data for semaglutide is now available from the SELECT trial, which showed a 20% reduction in major cardiovascular events — suggesting the benefits extend well beyond weight loss.

Q: Which GLP-1 drug has the fewest side effects?

All GLP-1 drugs share a similar GI side effect profile. In comparative data, nausea rates tend to be broadly similar between semaglutide and tirzepatide. Some patients find tirzepatide causes more nausea during escalation due to its dual mechanism; others tolerate it better than semaglutide. There is no universally “gentler” option — individual tolerance varies significantly. Starting at the lowest available dose and escalating slowly minimises side effects for any GLP-1 medication.

The Bottom Line

In the Ozempic vs Wegovy vs Mounjaro comparison, Mounjaro/Zepbound produces the most weight loss on average, Wegovy is the gold-standard semaglutide option for obesity treatment, and Ozempic is best suited to those managing type 2 diabetes. All three are effective, evidence-based treatments. The best choice is the one your doctor recommends based on your complete health profile — and the one you can take consistently for the long term.

Related articles:

• Semaglutide Weight Loss Timeline: Week by Week Results
• How Long Does Semaglutide Take to Work?
• Semaglutide Side Effects First Week: What to Expect

Sources:
Jastreboff AM et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387:205–216. SURMOUNT-1 summary: https://www.acc.org/latest-in-cardiology/clinical-trials/2022/08/04/15/32/surmount-1
Wilding JPH et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384:989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
Aronne LJ et al. “Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.” JAMA Intern Med. 2024. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080